These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38516474)

  • 41. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
    Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X; Xu C; Domagala J; Drlica K
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanism of plasmid-mediated quinolone resistance.
    Tran JH; Jacoby GA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.
    Aldred KJ; Breland EJ; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7182-7. PubMed ID: 25246407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.
    Hooper DC; Jacoby GA
    Cold Spring Harb Perspect Med; 2016 Sep; 6(9):. PubMed ID: 27449972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
    J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of quinolone action and microbial response.
    Hawkey PM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():29-35. PubMed ID: 12702701
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quinolones: a comprehensive review.
    Oliphant CM; Green GM
    Am Fam Physician; 2002 Feb; 65(3):455-64. PubMed ID: 11858629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
    Low DE; Muller M; Duncan CL; Willey BM; de Azavedo JC; McGeer A; Kreiswirth BN; Pong-Porter S; Bast DJ
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1119-21. PubMed ID: 11897603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Gyrase inhibitors, a new class of therapeutic drugs].
    Petzinger E
    Tierarztl Prax; 1991 Feb; 19(1):14-20. PubMed ID: 2048102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms involved in quinolone resistance in Mycoplasma mycoides subsp. capri.
    Antunes NT; Assunção P; Poveda JB; Tavío MM
    Vet J; 2015 Jun; 204(3):327-32. PubMed ID: 25951987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The fluoroquinolones.
    Walker RC; Wright AJ
    Mayo Clin Proc; 1991 Dec; 66(12):1249-59. PubMed ID: 1749294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Investigation of plasmid-mediated quinolone resistance determinants in Enterobacteriaceae: a multicenter study].
    Coban AY; Nohut OK; Tanrıverdi Çaycı Y; Bayramoğlu G; Pirinççiler M; Cetinkaya E; Cekiç Cihan C; Bozdoğan B; Durupınar B
    Mikrobiyol Bul; 2012 Jul; 46(3):366-74. PubMed ID: 22951649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
    Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
    Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.